
GUIDED THERAPEUTICS INC
100
Recent news coverage includes general market and sector news without company-specific developments. The company has ongoing regulatory and clinical milestones and international sales activities.
- Guided Therapeutics completed patient enrollment in the FDA-required clinical trial for LuViva and submitted the clinical module for FDA review in June 2026; FDA granted small business status and accepted the application for review [S1].
- The company established a wholly owned subsidiary in Turkey in March 2026, which has generated revenue from sales to the Turkish Ministry of Health and is conducting a clinical research study funded by the Ministry [S1,S2].
- Regulatory approval efforts continue in China with the NMPA manufacturing inspection completed in September 2026 and follow-up questions addressed; approval timing remains uncertain [S1].
- LuViva has regulatory approval in Russia since August 2025, but marketing efforts are complicated by the Russia-Ukraine conflict [S1].
- The company has received orders and payments from Indonesia but delayed shipment pending final payment for shipping and additional services [S1].
- Financial results for Q3 2026 show limited revenue of $92,000 and a net loss of $720,000, with liquidity ratios indicating tight liquidity [S2].
- The company faces substantial risks including financing needs, regulatory uncertainties, manufacturing challenges, and geopolitical risks [S1,S2].
- Recent broader market news includes topics such as Nvidia earnings, Fed minutes, and IPOs but does not directly relate to Guided Therapeutics [N1].
Guided Therapeutics Inc develops and markets the LuViva Advanced Cervical Scan, a non-invasive medical device designed to detect cervical cancer and precancers using biophotonics technology. The device offers a painless and rapid alternative to traditional cervical cancer screening methods, targeting both developing and developed markets. The company operates through direct sales and partnerships, with recent expansion including a wholly owned subsidiary in Turkey to facilitate sales to the Turkish Ministry of Health. Regulatory approvals are pursued globally, including ongoing FDA review in the United States, NMPA approval process in China, and existing approvals in Russia and other countries. The company has a history of operating losses and relies on additional financing and regulatory clearances to advance commercialization and growth.
Guided Therapeutics Inc is a medical technology company focused on the development and commercialization of the LuViva Advanced Cervical Scan device, a non-invasive cervical cancer detection technology. The company has reported limited revenues primarily from sales of LuViva devices and disposables, with $92,000 revenue and a net loss of $720,000 for Q3 2026. Liquidity ratios as of September 30, 2026, indicate tight liquidity with a current ratio of 0.11. The company has not yet obtained FDA approval but has completed clinical trials and submitted the clinical module for review. Regulatory approvals are also pursued in China, Europe, Russia, Turkey, and Indonesia. The company faces substantial risks including the need for additional financing, regulatory uncertainties, manufacturing scale-up challenges, and geopolitical risks. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company's LuViva device addresses a significant unmet need for non-invasive, rapid cervical cancer detection, potentially improving patient experience and reducing unnecessary follow-up procedures. Successful regulatory approvals in key markets such as the U.S., China, and Europe could enable broader commercialization. Strategic partnerships and direct sales efforts, including government collaborations in Turkey and Indonesia, may support revenue growth. The proprietary biophotonics technology and certifications provide a foundation for market differentiation.
Guided Therapeutics faces substantial risks including ongoing operating losses, tight liquidity, and the need for additional financing to sustain operations. Regulatory approvals remain uncertain and may face delays or denials, impacting commercialization. Manufacturing scale-up and supply chain challenges could hinder product availability. Geopolitical risks, including currency volatility and conflicts such as Russia-Ukraine, may adversely affect operations. The company has limited experience in manufacturing, marketing, and sales, which may impede growth and market acceptance.
Guided Therapeutics' moat is based on its proprietary biophotonics technology for non-invasive cervical cancer detection, which offers a unique value proposition of painless, rapid, point-of-care screening. The company's regulatory certifications such as ISO 13485:2016 and CE Mark, along with ongoing clinical trials and regulatory submissions, support its product credibility. However, the company faces significant challenges including regulatory approval uncertainties, limited manufacturing and marketing experience, and competition in the medical device industry, which may limit its competitive advantage.
• Financing Risk: The company requires additional capital to continue operations and product development. There is substantial doubt about its ability to continue as a going concern without securing additional funding on acceptable terms [S1].
• Regulatory Approval Risk: LuViva has not yet obtained FDA clearance or approval in the U.S. and faces uncertainties in regulatory approvals in China, Europe, and other markets. Delays or failure to obtain approvals could limit commercialization [S1].
• Operational and Manufacturing Risk: The company has limited experience in manufacturing and marketing. Achieving manufacturing scale-up and ensuring supply of critical components are challenges that could impact product availability and sales [S1].
• Geopolitical and Currency Risks: Operations are exposed to risks from geopolitical conflicts such as Russia-Ukraine and currency fluctuations, particularly with Turkish lira volatility, which may adversely affect financial results [S1,S2].
• Market Acceptance and Competition: The medical device industry is highly competitive with a high failure rate. The company may not achieve market acceptance or generate significant revenues [S1].
Business trends: Continued focus on regulatory approvals in the U.S., China, Europe, and expansion into emerging markets such as Turkey and Indonesia; ongoing clinical studies and limited product sales.
Execution milestones: Completion of FDA review process, potential regulatory approvals in China and other jurisdictions, scaling manufacturing and fulfilling existing orders, advancing clinical research collaborations.
Key risks: Need for additional financing to sustain operations, regulatory approval uncertainties, manufacturing and supply chain challenges, geopolitical and currency risks, and market acceptance in a competitive medical device industry.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Guided Therapeutics Inc is a medical technology company focused on developing and commercializing the LuViva Advanced Cervical Scan device, a non-invasive cervical cancer detection technology using biophotonics to scan the cervix with light and analyze reflected and fluorescent light [S1].
- LuViva aims to provide a painless, convenient, and rapid alternative to conventional cervical cancer screening tests, targeting both developing countries with limited infrastructure and developed countries as a triage tool to reduce unnecessary follow-up tests [S1].
- The company has been operating since 1992, originally as SpectRx, Inc., and changed its name to Guided Therapeutics, Inc. in 2008 [S1].
- Guided Therapeutics has a wholly owned subsidiary, GTHP Turkey, established in March 2026 to facilitate direct sales to the Turkish Ministry of Health, which has purchased devices generating revenue of approximately $56,000 in Q3 2026 [S1,S2].
- The company has limited historical revenues primarily from sales of LuViva devices and disposables, with approximately $92,000 revenue reported for the quarter ended September 30, 2026 [S2].
- As of September 30, 2026, the company had an accumulated deficit of approximately $159.4 million and reported a net loss of $720,000 for Q3 2026, with basic and diluted EPS of -$0.01 [S2].
- Liquidity ratios as of September 30, 2026, show a current ratio of 0.11 and cash ratio of 0.11, with cash and equivalents of $731,000 and current liabilities of $6,934,000, indicating tight liquidity [S2].
- The company has not yet obtained FDA clearance or approval for LuViva in the United States but completed patient enrollment in the required clinical trial with approximately 480 patients, no adverse events reported, and submitted the clinical module to FDA in June 2026 [S1].
- FDA granted small business status to Guided Therapeutics in July 2026, qualifying for a reduced user fee, which was paid in September 2026, allowing FDA review to continue; the company awaits FDA response [S1].
- LuViva has achieved and maintained ISO 13485:2016 certification and the CE Mark through its contract manufacturer Newmars Technologies, though the company is focusing on countries that do not require the CE Mark and its maintenance is uncertain [S1].
- The company is pursuing regulatory approvals in China through partners SMI, HDMT, and YMIC; the NMPA approval application was accepted in January 2025, with a manufacturing inspection conducted in September 2026 and follow-up questions addressed; potential approval timing is uncertain [S1].
- Guided Therapeutics has received regulatory approval for LuViva in Russia as of August 2025, but marketing efforts there are complicated by the ongoing Russia-Ukraine conflict [S1].
- The company is conducting a clinical research study with the Turkish Ministry of Health involving about 800 patients, funded by the Ministry, with approximately 300 patients enrolled as of Q3 2026 and study completion anticipated by January 2027 [S1].
- The company has received orders and payments for devices from Indonesia but delayed shipment pending final payment for shipping and additional services [S1].
- Guided Therapeutics faces substantial risks including the need for additional financing to continue operations, regulatory approval uncertainties, manufacturing scale-up challenges, competition, and geopolitical risks including currency fluctuations and impacts from the Russia-Ukraine conflict [S1,S2].
- The company has a history of operating losses and substantial accumulated deficit, with no assurance of achieving profitability or sufficient funding to continue as a going concern [S1].
- Guided Therapeutics' business model relies on sales of LuViva devices and disposables, regulatory approvals in multiple jurisdictions, and collaborations with distributors and partners internationally [S1].
Generated 2026-11-16
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-16 | www.nasdaq.com | This Is a Huge Week for the Stock Market: Nvidia Earnings, Fed Minutes, and Anthropic’s IPO | https://www.nasdaq.com/articles/huge-week-stock-market-nvidia-earnings-fed-minutes-and-anthropics-ipo
- N2 | 2026-11-16 | www.nasdaq.com | TOMI Environmental (TOMZ) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tomi-environmental-tomz-q3-2026-earnings-call-transcript
- N3 | 2026-11-16 | www.nasdaq.com | Corn Posting Midday Gains | https://www.nasdaq.com/articles/corn-posting-midday-gains-0
- N4 | 2026-11-16 | www.nasdaq.com | Millicom International Cellular S.A. Signs Agreement to Acquire Entel Peru for US$1,714 Million | https://www.nasdaq.com/articles/millicom-international-cellular-sa-signs-agreement-acquire-entel-peru-us-1714-million
- N5 | 2026-11-16 | www.nasdaq.com | IX Acquisition Corp. Enters Amendment No. 5 to Merger Agreement with AERKOMM Inc. | https://www.nasdaq.com/articles/ix-acquisition-corp-enters-amendment-no-5-merger-agreement-aerkomm-inc
- N6 | 2026-11-16 | www.nasdaq.com | The Bank of N.T. Butterfield & Son Limited Furnishes CIBC Caribbean Financials Ahead of $1,794 million Acquisition | https://www.nasdaq.com/articles/bank-nt-butterfield-son-limited-furnishes-cibc-caribbean-financials-ahead-1794-million
- N7 | 2026-11-16 | www.nasdaq.com | GameSquare Holdings (GAME) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/gamesquare-holdings-game-q3-2026-earnings-call-transcript
- N8 | 2026-11-16 | www.nasdaq.com | Virtuix (VTIX) Q2 2027 Earnings Call Transcript | https://www.nasdaq.com/articles/virtuix-vtix-q2-2027-earnings-call-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


